{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T18:19:40Z","timestamp":1715969980451},"reference-count":25,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2012,2,5]],"date-time":"2012-02-05T00:00:00Z","timestamp":1328400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> Recombinant immunoblot assay (RIBA) is used to determine the specificity of antibody to hepatitis\u2003C virus (anti\u2010HCV). The RIBA result is recorded as positive, negative, or indeterminate. The interpretation and significance of RIBA\u2010indeterminate reactions are unclear. We addressed the clinical relevance of these reactions in the context of the natural history of HCV infection in a prospectively followed cohort of anti\u2010HCV\u2013positive blood donors.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> Donor demographics, exposure history, and humoral and cell\u2010mediated immunity (CMI) were compared in 15 RIBA\u2010indeterminate subjects, nine chronic HCV carriers, and eight spontaneously recovered subjects. Serum samples were tested for anti\u2010HCV by a quantitative, liquid luciferase immunoprecipitation system (LIPS). CMI was assessed by interferon\u2010\u03b3 enzyme\u2010linked immunosorbent spot assay.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> In the LIPS assay, the sum of antibody responses to six HCV antigens showed significant (p\u2003&lt;\u20030.001) stepwise diminution progressing from chronic carriers to spontaneously recovered to RIBA\u2010indeterminate subjects. CMI responses in RIBA\u2010indeterminate subjects were similar to spontaneously recovered subjects and greater than chronic carriers and controls (p\u2003&lt;\u20030.008). A parenteral risk factor was identified in only 13% of RIBA\u2010indeterminate subjects compared to 89% of chronic carriers and 87% of spontaneously recovered subjects. RIBA\u2010indeterminate donors were older than the other groups.<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> The CMI and LIPS results suggest that persistent RIBA\u2010indeterminate reactions represent waning anti\u2010HCV responses in persons who have recovered from a remote HCV infection. In such cases, detectable antibody may ultimately disappear leaving no residual serologic evidence of prior HCV infection, as reported in a minority of long\u2010term HCV\u2010recovered subjects.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2011.03524.x","type":"journal-article","created":{"date-parts":[[2012,2,6]],"date-time":"2012-02-06T05:05:02Z","timestamp":1328504702000},"page":"1940-1948","source":"Crossref","is-referenced-by-count":18,"title":["The clinical relevance of persistent recombinant immunoblot assay\u2013indeterminate reactions: insights into the natural history of hepatitis C virus infection and implications for donor counseling"],"prefix":"10.1111","volume":"52","author":[{"given":"Addisalem T.","family":"Makuria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukanya","family":"Raghuraman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter D.","family":"Burbelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy C.","family":"Cantilena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert D.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Gibble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Rehermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey J.","family":"Alter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,5]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107053450107"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199208063270601"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(99)00373-3"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.3.41"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40010010.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.1.80-83.1996"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02113.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1586\/epr.11.23"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/75063"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.6.3447"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39133"},{"issue":"32","key":"e_1_2_7_13_2","first-page":"pii: 1549","article-title":"Antibody profiling by Luciferase Immunoprecipitation Systems (LIPS)","author":"Burbelo PD","year":"2009","journal-title":"J Vis Exp"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1086\/655780"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260711"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510260338"},{"key":"e_1_2_7_17_2","unstructured":"CDC.Hepatitis C FAQs for health professionals (monograph on the internet).2009."},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2496467"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310332"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)04719-4"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840190104"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.32.5.1357-1359.1994"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342602"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02103.x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.21905"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91691-1"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2011.03524.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2011.03524.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T15:24:24Z","timestamp":1697297064000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2011.03524.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,5]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1111\/j.1537-2995.2011.03524.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2011.03524.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,5]]}}}